GSK PLC (GSK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$51.15+5.03%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
QuarterlyIQ Insights · GSK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to long-term interest rates.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-04 · Compared with 10 industry peers · Company calendar date is not available
Why it matters: A return to higher revenue growth would signal a positive shift in the sector's maturity phase.
Supportive ifGSK reports Q3 revenue growth above 9% year over year.
Worry ifQ3 revenue growth remains below 9% year over year.
Why it matters: A drop in sector revenue growth could signal broader challenges for GSK and its peers.
Worry ifSector revenue growth falls below 3% year over year.
Less concerning ifSector revenue growth remains above 5% year over year.
Why it matters: The sector growth trend is easing. A return toward its recent highs would support a stronger sector backdrop.
Supportive ifThe sector's three-year revenue growth rises from near 9% toward its recent highs.
Worry ifThe sector's three-year revenue growth falls below 9% and keeps slowing.
Why it matters: Changes in peer performance can impact GSK's market position. Strong peers may attract investor interest.
Watch forAt least two peers (LLY, JNJ, ABBV, MRK, UNH) show improved composite insight scores above 20.
Also watch forAt least two peers show declining composite insight scores below 10.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$107 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $238 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,314 loss on $10,000 · 23.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: GSK reports on 2026-10-28. Its results and outlook can show how the business is doing.
Watch forThe release reports revenue growth above the sector's cited 9% three-year growth rate, or raises its outlook.
Also watch forThe release reports slowing revenue growth and cuts its outlook.
Why it matters: GSK's performance relative to peers like LLY and JNJ can indicate market strength.
Watch forGSK outperforms peers with a higher composite insight score than 15.
Also watch forGSK underperforms peers with a lower composite insight score than 10.
Why it matters: A drop in revenue growth could signal a slowdown in the company's performance. This could affect investor confidence in GSK's future.
Worry ifGSK's revenue growth falls below the sector median growth rate of 24%.
Less concerning ifGSK's revenue growth remains at or above the sector median growth rate.
Why it matters: Earnings results show how well GSK is doing. They also show its place in the sector.
Watch forGSK will share better earnings than expected on October 28.
Also watch forGSK will share earnings that are lower than what analysts expect on October 28.